| Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations |
|
Journal of Blood Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy |
|
Haematologica |
Aplastic Anemia |
| Myelodysplastic syndromes with ring sideroblasts |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia |
|
International Journal of Hematology |
Aplastic Anemia |
| Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
|
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
| Clinical decision‐making and treatment of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study |
|
Leukemia |
Aplastic Anemia |
